Dissolution test optimization for meloxicam in the tablet pharmaceutical form

• Autor(a) principal: Oliveira, Érika de Fátima Silva
• Data de Publicação: 2009
• Outros Autores: Azevedo, Roberta de Cássia Pimentel, Bonfilio, Rudy, Oliveira, Diego Borges de, Ribeiro, Gislaine Pereira, Araújo, Magali Benjamim de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/10655
• topic: Meloxicam^i2^sdissolu; Cinética de dissolução; Comprimidos^i2^steste de dissolu; Espectrofotometria; Meloxicam^i1^sdissolut; Dissolution kinetics; Tablet pharmaceutical forms^i1^sdissolution t; Spectrophotometry

Meloxicam is a broadly used drug in the therapeutics for the osteoarthritis and rheumatoid arthritis treatments in adults, and it is available in the Brazilian market, as tablet and capsule pharmaceutical forms. The present work aimed to establish conditions for accomplishment of the dissolution test of 15 mg meloxicam tablets (A and B test products), compared with the reference product, since there is no monograph about dissolution assays for meloxicam in official summaries. To optimize the conditions several parameters were tested and, according to obtained results, the use of pH 7.5 phosphate buffer (900mL, at 37 ± 0.5ºC) as dissolution medium, paddle method (apparatus 2), stirring speed of the dissolution medium at 100 rpm and collect time of 60 minutes were considered satisfactory. The samples were quantified by UV spectrophotometric method at 362 nm. The products presented kinetics of first-order. Dissolution efficiency values were of 83.25, 83.73 and 88.10% for the A, B and reference products, respectively. Factors f1 and f2 were calculated and similarity of the tested medicines was demonstrated. The dissolution test was validated presenting selectivity, linearity, precision and accuracy within of the acceptance criteria.